首页> 美国卫生研究院文献>Acta Pharmaceutica Sinica. B >Long non-coding RNAs: From disease code to drug role
【2h】

Long non-coding RNAs: From disease code to drug role

机译:长期非编码RNA:从疾病代码到药物角色

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Enormous studies have corroborated that long non-coding RNAs (lncRNAs) extensively participate in crucial physiological processes such as metabolism and immunity, and are closely related to the occurrence and development of tumors, cardiovascular diseases, nervous system disorders, nephropathy, and other diseases. The application of lncRNAs as biomarkers or intervention targets can provide new insights into the diagnosis and treatment of diseases. This paper has focused on the emerging research into lncRNAs as pharmacological targets and has reviewed the transition of lncRNAs from the role of disease coding to acting as drug candidates, including the current status and progress in preclinical research. Cutting-edge strategies for lncRNA modulation have been summarized, including the sources of lncRNA-related drugs, such as genetic technology and small-molecule compounds, and related delivery methods. The current progress of clinical trials of lncRNA-targeting drugs is also discussed. This information will form a latest updated reference for research and development of lncRNA-based drugs.
机译:巨大的研究已经证实,长期的非编码RNA(LNCRNA)广泛地参与了新陈代谢和免疫等关键生理过程,并且与肿瘤,心血管疾病,神经系统疾病,肾病和其他疾病的发生和发展密切相关。 LNCRNA作为生物标志物或干预目标的应用可以为疾病的诊断和治疗提供新的见解。本文的重点是作为药理靶标的新兴研究,并从疾病编码作为毒品候选者的作用,审查了LNCRNA的转型,包括当前状态和临床前研究中的进展。已经总结了LNCRNA调制的尖端策略,包括LNCRNA相关药物的来源,例如遗传技术和小分子化合物,以及相关的递送方法。还讨论了LNCRNA靶向药物的临床试验的进展情况。这些信息将为LNCRNA的毒品的研究和开发形成最新的最新更新参考。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号